<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036409</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMAL STROKE Trial</org_study_id>
    <nct_id>NCT04036409</nct_id>
  </id_info>
  <brief_title>Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients</brief_title>
  <acronym>OPTIMAL Stroke</acronym>
  <official_title>A Randomized Controlled Trial to Assess the Effect of Intensive Blood Pressure Control on Major Cardiovascular Events in Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elevated blood pressure (BP) consists of a major public health concern especially in low and
      middle income countries. Besides being a highly prevalent condition, it is also a risk factor
      for several major cardiovascular events including stroke (which consists of the second
      leading cause of death in developing countries) and coronary artery disease, and is also
      related to cognitive decline. The OPTIMAL Stroke trial consists of a two-arm, multicenter,
      randomized clinical trial designed to test whether a lower target systolic blood pressure
      (SBP) as compared to the currently recommended target for stroke patients will reduce the
      occurrence of major cardiovascular events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to non-fatal myocardial infarction (MI), non-fatal stroke or cardiovascular death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to a first occurrence of non-myocardial infarction (MI), non-fatal stroke or cardiovascular death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to non-fatal MI, non-fatal stroke, or total death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to non-fatal MI, non-fatal stroke or total death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to all cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cardiovascular Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to death from cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hemorrhagic Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to hemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ischemic Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to ischemic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Unclassified Stroke</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to unclassified stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Transient Ischemic Attack (TIA)</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Transient Ischemic Attack (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Myocardial Infarction (MI)</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to myocardial infarction (MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospitalization due to Heart Failure</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to hospitalization due to heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hospitalization due to Unstable Angina</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Hospitalization due to unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Renal Death</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to death from renal causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Renal Outcome</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Renal Outcome, defined as a 50% reduction in the glomerular filtration rate (GRF) associated with a final GFR of &lt; 60 mL/min/1.73m2 in patients without chronic kidney disease (GFR 60-90 mL/min/1.73m2) at baseline. In those patients with chronic kidney disease (&lt;60 mL/min/1.73m2) at baseline, the renal outcome will be defined as a 50% reduction in GFR or progression of renal disease to stage IV, requiring dialysis or kidney transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a Composite Outcome of Mild Cognitive Impairment or Probable All Cause Dementia</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Occurrence of mild cognitive impairment or probable all-cause dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Mild Cognitive Impairment</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to Mild Cognitive Impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to All-Cause Probable Dementia</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Time to all-cause probable dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Brain Volume</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>Total Brain Volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White Matter Lesions Volume</measure>
    <time_frame>From randomization; for approximately a median of 3.5 years</time_frame>
    <description>White Matter Lesions Volume</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7104</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Blood Pressure</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Intensive Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized into the Intensive Blood Pressure arm will have a goal of SBP &lt;120 mm Hg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Control of Systolic Blood Pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized into the Standard arm will have a goal of SBP &lt;140 mm Hg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive Control of Systolic Blood Pressure (SBP)</intervention_name>
    <description>Participants in the Intensive arm have a goal of SBP &lt;120 mm Hg. Use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged.</description>
    <arm_group_label>Intensive Control of Systolic Blood Pressure (SBP)</arm_group_label>
    <other_name>Intensive BP control targeting SBP &lt;120 mmHg.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard control of Systolic Blood Pressure (SBP)</intervention_name>
    <description>he same medications used in the Intensive BP arm will be used for the Standard BP arm.</description>
    <arm_group_label>Standard Control of Systolic Blood Pressure</arm_group_label>
    <other_name>Standard control of SBP targeting SBP &lt; 140 mmHg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of ischemic stroke or transient ischemic attack (TIA), considered clinically
             stable in the two weeks prior to inclusion in the study. (they will be classified into
             a recent stroke &lt;120 days or chronic when&gt; 120 days), AND

          -  Systolic Blood Pressure (SBP) between 130 and 180 mmHg:

               -  130 -180 and use of up to one antihypertensive drug;

               -  130-170 and use of up to two drugs;

               -  130-160 and use of up to three drugs;

               -  130-150 and use of up to four drugs. AND

          -  To be considered as having a high cardiovascular risk, including at least one of the
             cardiovascular risk factors among those listed below:

               1. Presence of clinically manifested Cardiovascular Disease:

                    -  Coronary Artery Disease: anterior myocardial infarction, myocardial
                       Revascularization, Percutaneous Angiography; previous acute coronary
                       syndrome; previous percutaneous coronary intervention, myocardial
                       revascularization surgery, coronary artery stenosis of at least 50%
                       associated with angina pectoris.

                    -  Carotid disease: Asymptomatic carotid stenosis of at least 50% as evidenced
                       by Doppler ultrasonography, computorized tomography (CT) angiography or
                       magnetic resonance (MR) angiography, prior endarterectomy or previous
                       carotid stent.

                    -  Peripheral artery disease: prior surgical or percutaneous revascularization
                       of a peripheral artery, amputation due to vascular cause, abdominal aortic
                       aneurysm&gt; = 5 cm (with or without surgical or percutaneous repair) or
                       stenosis of at least 50% in a peripheral artery associated with intermittent
                       claudication.

               2. Subclinical cardiovascular disease:

                    -  Coronary Artery Calcium Index ≥ 300 Agatston in the last two years

                    -  Ankle-brachial index &lt;= 0.9 in the last two years.

                    -  Left ventricular hypertrophy evidenced by EKG, Ultrasound or other cardiac
                       imaging in the last two years.

               3. At least one of the risk factors below::

                    -  Age ≥ 75 years

                    -  Type II Diabetes

                    -  Chronic kidney disease (CKD), defined as: glomerular filtration rate between
                       20 and 59 mL/min/1.73m2 calculated by the Chronic Kidney Disease
                       Epidemiology Collaboration (CKD-EPI).

                    -  Dyslipidemia, defined as LDL cholesterol 70 mg/dL in patients with previous
                       CVD or LDL&gt; mg/dL in patients without previous cardiovascular disease (CVD),
                       triglycerides&gt; 200 mg/dL, non-HDL cholesterol &gt; 100 mg/dL or regular use of
                       statins or other lipid-lowering agents.

                    -  Active smoking, defined as: regular use of cigarettes or other tobacco
                       products, such as cigars and pipe, in the last six months.

        Exclusion Criteria:

          -  History of primary intracranial hemorrhage;

          -  Severe disability after the event that qualified the patient for the study, defined as
             a modified Rankin (mRankin) scale equal to or greater than 4.

          -  Being part of another clinical trial involving interventions for cardiovascular
             prevention.

          -  Body mass index &gt; 45 kg/m2.

          -  Pregnancy or Breastfeeding.

          -  Secondary hypertension.

          -  Class IV Canadian Cardiovascular Society (CCS) Resting Angina.

          -  Acute coronary syndrome in the last six months

          -  Severe renal dysfunction with GFR &lt; 20 mL/min/1.73m2 calculated by the CKD-EPI
             equation

          -  Refusal to consent.

          -  Symptomatic heart failure - Class IV New York Heart Association (NYHA) or ejection
             fraction &lt;35% on Doppler echocardiography.

          -  Conditions that, at the investigators' discretion, limit the patient's participation
             in the study, including but not limited to the following:

               -  Recent history of alcohol and illicit drug abuse.

               -  Psychiatric comorbidities (severe depression, schizophrenia, psychosis, etc.).

               -  History of poor drug adherence and no attendance at consultations.

               -  Planning to change of address in the next four years.

               -  Planning to be absent from home city for more than three months in the next year.

               -  Residing in the same residence of another patient previously included in this
                  study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otavio Berwanger, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Julia Machline Carrion, MD, PhD</last_name>
    <phone>11 2151-5915</phone>
    <phone_ext>75915</phone_ext>
    <email>julia.carrion@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gisele Sampaio Silva, MD, PhD</last_name>
    <phone>11 2151-5915</phone>
    <phone_ext>75915</phone_ext>
    <email>gisele.sampaio@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Ana Nery</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40323-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz Carlos S Passos, MD, PhD</last_name>
      <phone>(71) 3117-1800</phone>
      <email>luizcarlos@han.net.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Hospitalar de Base Do Distrito Federal</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70335900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia Rebello, MD</last_name>
      <phone>5561999150626</phone>
      <email>letirebello@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Goias</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74690-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weimar Kunz Sebba Barroso de Souza, MD, PhD</last_name>
      <phone>(62) 3521-1000</phone>
      <email>Sebbabarroso@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flumignano Instituto de Medicina</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>82590-300</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Zetola, MD, PhD</last_name>
      <phone>(41) 3264-7500</phone>
      <email>viviane.zetola@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PROCAPE-Pronto Socorro Cardiológico de PE Prof. Luiz Tavares</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>74970-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audes Feitosa, MD</last_name>
      <phone>5581999961302</phone>
      <email>audesfeitosa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Moinho de Ventos</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo A Carbonera, MD, Msc</last_name>
      <phone>(51) 99141-5026</phone>
      <email>leonardoacarbonera@gmail.comleonardoacarbonera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-007</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flávio Danni Fuchs, MD, PhD</last_name>
      <phone>(51) 3359-8000</phone>
      <email>ffuchs@hcpa.edu.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Governador Celso Ramos</name>
      <address>
        <city>Florianópolis</city>
        <state>Santa Catarina</state>
        <zip>88015-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gladys Lentz Martins, MD</last_name>
      <phone>(48) 3251-7000</phone>
      <email>glentz63@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Neurológica e Neurocirurgica de Joinville LTDA</name>
      <address>
        <city>Joinville</city>
        <state>Santa Catarina</state>
        <zip>89202-165</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Moro, MD, PhD</last_name>
      <phone>(47) 3451-2525</phone>
      <email>carlahcmoro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rubens Gagliardi, MD, PhD</last_name>
      <phone>11 2176.7000</phone>
      <email>rubensjg@apm.org.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Vilela e Martin</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15090-365</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Fernando Vilela Martin, MD, PhD</last_name>
      <phone>17 3353-7007</phone>
      <email>vilelamartin@uol.com.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundação Faculdade Regional de Medicina de São José do Rio Preto</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <zip>150900000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilia Nigro Maia, MD, PhD</last_name>
      <phone>55 17 991495710</phone>
      <email>liliannigromaia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Pedro Ernesto - UERJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea A Brandão, MD, PhD</last_name>
      <phone>(21) 2868-8000</phone>
      <email>andreaaraujobrandao@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da FMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>(11) 2661-0000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Ferreira Drager, MD, PhD</last_name>
      <phone>(11) 2661-0000</phone>
      <email>luciano.drager@hc.fm.usp.br</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Conforto, MD, PhD</last_name>
      <phone>(11) 2661-0000</phone>
      <email>adriana.conforto@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04037-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisele S Silva, MD, MPH, PhD</last_name>
      <phone>(11)5579-2581</phone>
      <email>giselesampaio@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maramelia M Alves, MD, MSc</last_name>
      <phone>(11)5579-2581</phone>
      <email>marameliamiranda@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>InCor - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiz A Bortolotto, MD, PhD</last_name>
      <phone>(11) 2661-5000</phone>
      <email>luiz.bortolotto@incor.usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

